TradeFlare's AI research teams analysed EXEL on 6 market nights between May 7, 2026 and September 21, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 21, 2026 | BUY | $58.36 | $65.36 / $52.52 | +2.0% | not yet | The stock is showing momentum continuation and the fundamental outlook supports a medium-term upward trend. |
| August 6, 2026 | BUY | $56.70 | — / — | -3.0% | +13.3% | Waiting for a clearer technical signal and improved risk-reward. |
| May 12, 2026 | BUY | $49.71 | — / — | -1.6% | +6.3% | Continued positive impact from Q1 earnings surprise and PEAD signal. |
| May 11, 2026 | BUY | $48.16 | — / — | +0.3% | +6.6% | Continued positive momentum from strong Q1 earnings and EPS beat. |
| May 8, 2026 | BUY | $46.21 | — / — | +4.1% | +7.4% | Continued strong performance of the cabozantinib franchise. |
| May 7, 2026 | BUY | $48.70 | $56.00 / $43.83 | +10.6% | +14.0% | The stock is poised for a breakout above resistance, supported by strong fundamentals and positive sentiment, with a target aligned with the bullish market regime. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.